After launching last month, Vitaeris has got its hands on a new inflammatory disease candidate from Alder BioPharmaceuticals--while the Bothell, WA, biotech’s CEO ...
Alder BioPharmaceuticals has licensed exclusive worldwide rights to its Phase II inflammation candidate clazakizumab to a newly formed company for an undisclosed sum, the companies said today. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results